Adrian Höveler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adrian Höveler has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Kötting
Center for Protein Diagnostics (PRODI), Biospectroscopy, Ruhr University Bochum, Bochum, Germany
5 shared publications - Jonas Simon
Ruhr University Bochum
4 shared publications - Klaus Gerwert
Ruhr University Bochum
4 shared publications - Marvin Mann
Center for Protein Diagnostics (PRODI)
4 shared publications - Grischa Gerwert
Ruhr-University Bochum
2 shared publications Jörn Güldenhaupt
Center for Protein Diagnostics (PRODI)
2 shared publications
Latest Publications
- Open Access
- 24 April 2026
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 130 (18) , 4711-4719
An Immuno-Infrared Sensor Detects Preclinical Alzheimer’s and Parkinson’s Disease by Protein Misfolding
The immuno-infrared sensor (iRS) detects misfolding of biomarker proteins in blood and provides thereby a very early and easily accessible diagnosis of Alzheimer’s and Parkinson’s disease. Only in early stages recently approved therapeutic Alzheimer′s drugs work efficiently. In symptom-free stages, lifestyle change can largely delay the disease progression, and the drugs may even block the disease progression. Population screening by a simple blood test will therefore be a game changer in the fight against neurodegenerative diseases. This was made possible by the new iRS platform. In the iRS platform, antibodies as catcher molecules concentrate the target protein biomarker on the functionalized attenuated total reflection crystal surface. A blocking layer prevents unspecific binding. A quantum cascade laser is used to measure the amide I absorbance maximum as a readout, indicating the degree of the biomarker misfolding and thereby disease progression.
- 24 April 2026
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 130 (18) , 4711-4719
Open AccessAn Immuno-Infrared Sensor Detects Preclinical Alzheimer’s and Parkinson’s Disease by Protein Misfolding
The immuno-infrared sensor (iRS) detects misfolding of biomarker proteins in blood and provides thereby a very early and easily accessible diagnosis of Alzheimer’s and Parkinson’s disease. Only in early stages recently approved therapeutic Alzheimer′s drugs work efficiently. In symptom-free stages, lifestyle change can largely delay the disease progression, and the drugs may even block the disease progression. Population screening by a simple blood test will therefore be a game changer in the fight against neurodegenerative diseases. This was made possible by the new iRS platform. In the iRS platform, antibodies as catcher molecules concentrate the target protein biomarker on the functionalized attenuated total reflection crystal surface. A blocking layer prevents unspecific binding. A quantum cascade laser is used to measure the amide I absorbance maximum as a readout, indicating the degree of the biomarker misfolding and thereby disease progression.
- 16 April 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (16) , 11935-11943
A Reversible ATR-FTIR Biosensor with Single-Residue Sensitivity
Infrared spectroscopy provides label-free access to protein structure information with high sensitivity. Challenges in infrared spectroscopy include artifacts arising from temperature changes, baseline drifts, and the strong water absorption, especially in difference spectroscopy, where signals are orders of magnitude smaller than the total absorbance. Previously, we introduced an ATR-based immuno-infrared sensor (iRS) based on sophisticated surface chemistry. This provides a stable platform for covalent protein immobilization and allows its application with body fluids such as cerebrospinal fluid or blood without unspecific background. It detects misfolding of small amounts of antigen (Aβ or α-synuclein) by binding to an antibody or antibody fragment, which allows for the diagnosis of various neurodegenerative diseases. Here, we extend this platform by introducing reversible binding via the NColE7/Im7 pair. Im7-tagged proteins are captured with subpicomolar affinity and quantitatively released under mild conditions (high salt or low pH), allowing repeated capture-regeneration cycles with continuous spectral monitoring of the Im7 fusion protein. Using an Im7-antibody Fab fusion protein, we present a reusable immuno-IR sensor that enables multiple measurements on the same surface. For example, different antibodies can be used for differential screening. Using alternating Im7 protein attachments to the internal reflection element, we further compare Im7 single point mutants to wild-type Im7 to resolve infrared signatures of specific amino acid substitutions. Difference spectra reveal the distinct tyrosine absorption associated with either the introduction or removal of a single tyrosine residue, providing a proof-of-concept for single-residue sensitivity in infrared difference spectroscopy enabled by complete protein exchange instead of induced perturbations on the same protein.
- 16 April 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (16) , 11935-11943
A Reversible ATR-FTIR Biosensor with Single-Residue Sensitivity
Infrared spectroscopy provides label-free access to protein structure information with high sensitivity. Challenges in infrared spectroscopy include artifacts arising from temperature changes, baseline drifts, and the strong water absorption, especially in difference spectroscopy, where signals are orders of magnitude smaller than the total absorbance. Previously, we introduced an ATR-based immuno-infrared sensor (iRS) based on sophisticated surface chemistry. This provides a stable platform for covalent protein immobilization and allows its application with body fluids such as cerebrospinal fluid or blood without unspecific background. It detects misfolding of small amounts of antigen (Aβ or α-synuclein) by binding to an antibody or antibody fragment, which allows for the diagnosis of various neurodegenerative diseases. Here, we extend this platform by introducing reversible binding via the NColE7/Im7 pair. Im7-tagged proteins are captured with subpicomolar affinity and quantitatively released under mild conditions (high salt or low pH), allowing repeated capture-regeneration cycles with continuous spectral monitoring of the Im7 fusion protein. Using an Im7-antibody Fab fusion protein, we present a reusable immuno-IR sensor that enables multiple measurements on the same surface. For example, different antibodies can be used for differential screening. Using alternating Im7 protein attachments to the internal reflection element, we further compare Im7 single point mutants to wild-type Im7 to resolve infrared signatures of specific amino acid substitutions. Difference spectra reveal the distinct tyrosine absorption associated with either the introduction or removal of a single tyrosine residue, providing a proof-of-concept for single-residue sensitivity in infrared difference spectroscopy enabled by complete protein exchange instead of induced perturbations on the same protein.
- Open Access
- 12 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
A Reversible ATR-FTIR Biosensor with Single Residue Sensitivity
Infrared spectroscopy provides label-free access to protein structure information with high sensitivity. Challenges in infrared spectroscopy include artifacts arising from temperature changes, baseline drifts and the strong water absorption, especially in difference spectroscopy, where signals are orders of magnitude smaller than the total absorbance. Previously, we introduced an ATR-based immuno-infrared sensor (iRS) based on sophisticated surface chemistry. This provides a stable platform for covalent protein immobilization and allows its application with body fluids such as cerebrospinal fluid or blood without unspecific background. It detects misfolding of small amounts of antigen (Abeta or alpha-synuclein) by binding to an antibody or antibody fragment, which allows for the diagnosis of various neurodegenerative diseases. Here, we extend this platform by introducing reversible binding via the NColE7/Im7 pair. Im7-tagged proteins are captured with sub-picomolar affinity and quantitatively released under mild conditions (high salt or low pH), allowing repeated capture-regeneration cycles with continuous spectral monitoring of the Im7 fusion protein. Using an Im7-antibody Fab fusion protein, we present a reusable immune-IR sensor that enables multiple measurements on the same surface. For example, different antibodies can be used for differential screening. Using alternating Im7 protein attachments to the internal reflection element, we further compare Im7 single point mutants to wild-type Im7 to resolve infrared signatures of specific amino acid substitutions. Difference spectra reveal the distinct tyrosine absorption associated with either the introduction or removal of a single tyrosine residue, providing the first proof-of-concept for difference spectroscopy with single-residue sensitivity based on complete protein exchange.
- 12 January 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Reversible ATR-FTIR Biosensor with Single Residue Sensitivity
Infrared spectroscopy provides label-free access to protein structure information with high sensitivity. Challenges in infrared spectroscopy include artifacts arising from temperature changes, baseline drifts and the strong water absorption, especially in difference spectroscopy, where signals are orders of magnitude smaller than the total absorbance. Previously, we introduced an ATR-based immuno-infrared sensor (iRS) based on sophisticated surface chemistry. This provides a stable platform for covalent protein immobilization and allows its application with body fluids such as cerebrospinal fluid or blood without unspecific background. It detects misfolding of small amounts of antigen (Abeta or alpha-synuclein) by binding to an antibody or antibody fragment, which allows for the diagnosis of various neurodegenerative diseases. Here, we extend this platform by introducing reversible binding via the NColE7/Im7 pair. Im7-tagged proteins are captured with sub-picomolar affinity and quantitatively released under mild conditions (high salt or low pH), allowing repeated capture-regeneration cycles with continuous spectral monitoring of the Im7 fusion protein. Using an Im7-antibody Fab fusion protein, we present a reusable immune-IR sensor that enables multiple measurements on the same surface. For example, different antibodies can be used for differential screening. Using alternating Im7 protein attachments to the internal reflection element, we further compare Im7 single point mutants to wild-type Im7 to resolve infrared signatures of specific amino acid substitutions. Difference spectra reveal the distinct tyrosine absorption associated with either the introduction or removal of a single tyrosine residue, providing the first proof-of-concept for difference spectroscopy with single-residue sensitivity based on complete protein exchange.
- Open Access
MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE
Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are characterized by pathological aggregation of misfolded alpha-synuclein (αSyn) in the central and peripheral nervous systems. Seed amplification assays (SAAs) can detect misfolded αSyn in cerebrospinal fluid (CSF), allowing a more precise biological classification of these diseases. Translating biomarker-based diagnostics to blood represents a crucial milestone to democratize access to molecular testing, as blood sampling is minimally invasive and widely scalable. However, current blood-based SAA approaches require extensive sample preprocessing, which introduces variability and has yielded inconsistent results. Here, we present the immuno-infrared-sensor (iRS) platform, which detects misfolded αSyn directly in blood serum without sample preprocessing and without amplification. The iRS measures the secondary-structure distribution of αSyn by distinguishing α-helical/random-coil monomers from β-sheet-rich oligomers and fibrils. This conformational distribution reflects disease-associated structural changes in blood and provides information beyond the binary readout of SAAs. In a combined cohort (n = 127) consisting of 74 individuals with synucleinopathies (PD, DLB, MSA and isolated rapid eye movement sleep behavior disorder (iRBD)) and 53 controls, the assay achieved a receiver operating characteristic area under the curve (ROC AUC) of 0.94 (95% confidence interval (CI), 0.88–0.99), with 88% sensitivity and 89% specificity in serum using a dual-threshold classification that categorized individuals as controls (no misfolding, green), at risk (low misfolding, yellow) or diseased (high misfolding, red). By extending the iRS platform from CSF to blood serum, this study demonstrates αSyn misfolding as a promising blood-based structural biomarker for synucleinopathies. The iRS assay provides a broadly applicable platform technology for more precise biological classification, disease monitoring and assessment of drug response for PD in peripheral blood.
Open AccessMISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE
Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are characterized by pathological aggregation of misfolded alpha-synuclein (αSyn) in the central and peripheral nervous systems. Seed amplification assays (SAAs) can detect misfolded αSyn in cerebrospinal fluid (CSF), allowing a more precise biological classification of these diseases. Translating biomarker-based diagnostics to blood represents a crucial milestone to democratize access to molecular testing, as blood sampling is minimally invasive and widely scalable. However, current blood-based SAA approaches require extensive sample preprocessing, which introduces variability and has yielded inconsistent results. Here, we present the immuno-infrared-sensor (iRS) platform, which detects misfolded αSyn directly in blood serum without sample preprocessing and without amplification. The iRS measures the secondary-structure distribution of αSyn by distinguishing α-helical/random-coil monomers from β-sheet-rich oligomers and fibrils. This conformational distribution reflects disease-associated structural changes in blood and provides information beyond the binary readout of SAAs. In a combined cohort (n = 127) consisting of 74 individuals with synucleinopathies (PD, DLB, MSA and isolated rapid eye movement sleep behavior disorder (iRBD)) and 53 controls, the assay achieved a receiver operating characteristic area under the curve (ROC AUC) of 0.94 (95% confidence interval (CI), 0.88–0.99), with 88% sensitivity and 89% specificity in serum using a dual-threshold classification that categorized individuals as controls (no misfolding, green), at risk (low misfolding, yellow) or diseased (high misfolding, red). By extending the iRS platform from CSF to blood serum, this study demonstrates αSyn misfolding as a promising blood-based structural biomarker for synucleinopathies. The iRS assay provides a broadly applicable platform technology for more precise biological classification, disease monitoring and assessment of drug response for PD in peripheral blood.
- Open Access
Replacement of a single residue in an antibody completely abolishes cognate antigen binding, as predicted by theoretical methods
Structural insights into the interaction between antibodies and antigens at the atomic level are pivotal for understanding the molecular mechanisms of antigen binding. Despite the availability of structural models generated by recent artificial intelligence advancements, computational predictions require experimental validation to confirm their accuracy. Here, we demonstrate a novel approach that combines computational protein modeling with spectroscopic experiments to validate antibody-antigen interactions. As a case example we use solanezumab, a monoclonal antibody that targets amyloid-beta (Aβ), whose misfolding is the main factor responsible for Alzheimer’s disease. For this antibody we predicted a single mutation, G95A HC , within the paratope of the heavy chain to disrupt antigen binding. This mutation, referred to as a “dead mutant”, was experimentally validated using an immuno-infrared biosensor (iRS). Our results confirmed that the mutation abolished antigen binding without affecting the native structure of the antibody. The use of dead mutants enables precise differentiation between specific and nonspecific binding, which is particularly important in medical diagnostics. We applied this approach to analyze the binding of solanezumab to synthetically produced Aβ variants and Aβ catched by the iRS functionalized surface from cerebrospinal fluid, showcasing its utility in Alzheimer’s disease diagnostics. These findings highlight the value of computational modeling and experimental validation in understanding antigen-antibody interactions, with significant implications for diagnostic and therapeutic applications.
Open AccessReplacement of a single residue in an antibody completely abolishes cognate antigen binding, as predicted by theoretical methods
Structural insights into the interaction between antibodies and antigens at the atomic level are pivotal for understanding the molecular mechanisms of antigen binding. Despite the availability of structural models generated by recent artificial intelligence advancements, computational predictions require experimental validation to confirm their accuracy. Here, we demonstrate a novel approach that combines computational protein modeling with spectroscopic experiments to validate antibody-antigen interactions. As a case example we use solanezumab, a monoclonal antibody that targets amyloid-beta (Aβ), whose misfolding is the main factor responsible for Alzheimer’s disease. For this antibody we predicted a single mutation, G95A HC , within the paratope of the heavy chain to disrupt antigen binding. This mutation, referred to as a “dead mutant”, was experimentally validated using an immuno-infrared biosensor (iRS). Our results confirmed that the mutation abolished antigen binding without affecting the native structure of the antibody. The use of dead mutants enables precise differentiation between specific and nonspecific binding, which is particularly important in medical diagnostics. We applied this approach to analyze the binding of solanezumab to synthetically produced Aβ variants and Aβ catched by the iRS functionalized surface from cerebrospinal fluid, showcasing its utility in Alzheimer’s disease diagnostics. These findings highlight the value of computational modeling and experimental validation in understanding antigen-antibody interactions, with significant implications for diagnostic and therapeutic applications.